Daiichi Sankyo Receives the First Approval for its Blood Cancer Drug Ezharmia Daiichi Sankyo has received the first global approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL). The Japanese Ministry of ...
Find MoreNovo Nordisk Reports Phase III Results of Concizumab Drug for Hemophilia A or B Novo Nordisk has announced Phase III results for their concizumab drug for hemophilia A or B, demonstrating efficacy in preventing bleeding events and paving the way for regulatory filings later this year. Concizumab, an anti-tissue ...
Find MoreGSK Starts Preparations for Regulatory Filings as RSV Vaccine Clears Phase III Test in Adults GSK plans to initiate preparation for regulatory submissions for its respiratory syncytial virus (RSV) vaccine after the vaccine performed well in the much-anticipated AReSVi 006 trial in individuals aged 60 and above.&...
Find MoreChimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative potential as a new type of cancer treatment that utilizes the immune system to fight the disease. It involves the process where genetically engineered T cells (patient/donor) express a chimeric antigen receptor to target a specific ...
Find MoreMorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymp...
Find MoreAs per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030. During the course of past decades, with the advancement in technology and a clear understanding of the molecular patho...
Find MoreMultiple Myeloma, the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due to the presence of malignant plasma cells in bone marrow. Due to the vigorous proliferation of highly abnormal, unstable cells circulating via the bloodstream and lymph nodes, ...
Find MoreSutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple my...
Find MorePositive Phase 2 data for Roche’s lymphoma ADC Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab has already received breakthrough designation from the USFDA and priority medicine status in the EU, and the expectations for the same are running pretty high. Phase 2 data presented by the company at...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.